CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
390.57MUSDvs all stocks (USD)
Revenue (TTM)
99.61MUSDvs all stocks (USD)
Profit Margin
-154.21%vs Biotechnology peers
Beta
1.52xvs all stocks
52-Week Change
194.63%vs all stocks
Market Capitalization
390.57MUSDvs all stocks (USD)
Enterprise Value
201.64MUSDvs all stocks (USD)
Forward P/E
-3.42xvs Biotechnology peers
Price to Sales (TTM)
3.92xvs Biotechnology peers
Enterprise to Revenue
2.02xvs Biotechnology peers
Enterprise to EBITDA
-2.51xvs Biotechnology peers
Profit Margin
-154.21%vs Biotechnology peers
Operating Margin
-203.91%vs Biotechnology peers
Return on Assets (TTM)
-19.32%vs Biotechnology peers
Revenue (TTM)
99.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
10.29USDUpdated Jul 19, 2026Quarterly Revenue Growth
-16.50%vs Biotechnology peers
Gross Profit (TTM)
-65.33MUSDvs all stocks (USD)
EBITDA (TTM)
-80.39MUSDvs all stocks (USD)
Net Income (TTM)
-153.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-16.53%vs Biotechnology peers
Operating Cash Flow (TTM)
-151.61MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-106.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
102.48MUSDFY2025 · Dec 31, 2025Operating Income
-104.95MUSDvs all stocks (USD)
Pre-tax Income
-191.18MUSDFY2025 · Dec 31, 2025Income Tax Expense
-93.00KUSDFY2025 · Dec 31, 2025Net Income
-191.09MUSDFY2025 · Dec 31, 2025EBIT
-149.12MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-88.38MUSDFY2025 · Dec 31, 2025Research & Development
166.42MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.02MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
42.06MUSDFY2025 · Dec 31, 2025EPS (Basic)
-22.49USDFY2025 · Dec 31, 2025EPS (Diluted)
-22.49USDFY2025 · Dec 31, 2025Basic Shares Outstanding
8.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
8.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-191.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-198.39MUSDFY2025 · Dec 31, 2025Free Cash Flow
-200.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
58.99MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-191.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
44.66MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.64MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.47MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-75.47MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.70MUSDFY2025 · Dec 31, 2025Purchase of Investments
-264.95MUSDFY2025 · Dec 31, 2025Sale of Investments
311.66MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
45.01MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-332.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-332.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
16.57MSharesUpdated Jul 19, 2026Float Shares
10.30MSharesUpdated Jul 19, 2026Shares Short
1.36MSharesUpdated Jul 19, 2026Short Ratio
3.33daysvs all stocks
Short % of Shares Outstanding
8.24%vs all stocks
% Held by Insiders
2.26%vs all stocks
% Held by Institutions
87.40%vs all stocks
Total Cash (MRQ)
202.56MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.22USDUpdated Jul 19, 2026Total Debt (MRQ)
13.63MUSDvs all stocks (USD)
Current Ratio (MRQ)
3.12xvs Biotechnology peers
Book Value per Share (MRQ)
-4.04USDUpdated Jul 19, 2026Total Assets
173.83MUSDvs all stocks (USD)
Total Current Assets
150.93MUSDFY2025 · Dec 31, 2025Total Liabilities
306.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
231.15MUSDFY2025 · Dec 31, 2025Total Current Liabilities
75.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
58.13MUSDFY2025 · Dec 31, 2025Other Short-term Investments
83.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.98MUSDFY2025 · Dec 31, 2025Accounts Payable
7.57MUSDFY2025 · Dec 31, 2025Short-term Debt
7.78MUSDFY2025 · Dec 31, 2025Deferred Revenue
10.56MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.91MUSDFY2025 · Dec 31, 2025Long-term Debt
7.89MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-977.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-132.45MUSDvs all stocks (USD)
52-Week Low
7.15USDUpdated Jul 19, 202652-Week High
43.85USDUpdated Jul 19, 202652-Week Change
194.63%vs all stocks
Beta
1.52xvs all stocks
50-Day MA
30.83USDUpdated Jul 19, 2026200-Day MA
19.89USDUpdated Jul 19, 2026Avg 10-Day Volume
337.87KSharesUpdated Jul 19, 2026Avg 30-Day Volume
399.36KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-16.35USDUpdated Jul 19, 2026Other Income / Expense
-53.41MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Favite Inc.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Taiwan Semiconductor Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Xi'an Typical Industries Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated